GRCE - Grace Therapeutics, Inc. Operating profit before deduction of amortization
Sales expansion in the US and Europe reduces the risks of regional dependency for Grace Therapeutics, Inc. (GRCE), and the EBITDA level reflects the dynamics of this process, where 0.00 shows the current value of the metric. Efficiency is increasing due to unique drug delivery systems, while stable demand for biotechnology protects the business from global recessions and macroeconomic volatility.
Grace Therapeutics (GRCE) - metric breakdowns and financial figures
- market price and analyst price targets:
- market capitalization statistics:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Aggregate Debt to Capital Grace Therapeutics, Inc.|GRCE - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Grace Therapeutics Inc|GRCE - Company Aggregate Debts|Debts to Book Value Grace Therapeutics|GRCE - Company Long-Term Debt|Company Short-Term Loans and Borrowings Grace Therapeutics|Quick Ratio gracetx.com
- earnings and market multiples details:
GRCE - Company Net Income|Forward Earnings Grace Therapeutics, Inc.|GRCE - P/E Multiple|Projected Price to Earnings Ratio Grace Therapeutics Inc|GRCE - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Grace Therapeutics|GRCE - Operating profit before deduction of amortization|Earnings per share for the last four quarters Grace Therapeutics|GRCE - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months gracetx.com|GRCE - Earnings growth in current year|Expected earnings per share growth for next year Grace Therapeutics, Inc.
- sales and revenue indicators:
Summary company analytics:Grace Therapeutics, Inc.
Grace Therapeutics, Inc. (GRCE) focuses on creating innovative molecule delivery systems across the blood-brain barrier for the therapy of rare neurological pathologies. This metric measures net cash flow from operating activities before depreciation and taxes, reflecting the efficiency of R&D processes; meanwhile, the narrow sideways corridor of absolute operating cash results signals a consolidation of demand ahead of a new fundamental impulse.
Competitors of Grace Therapeutics, Inc. (GRCE)
Operating profit EBITDA Biogen Idec BIIB|Neurocrine Biosciences - Operating profit EBITDA|regencellbioscience.com (RGC) - Operating profit before deduction of amortization|AXSM: Operating profit EBITDA|Profit before interest, taxes and amortization ACADIA Pharma (ACAD)|Operating profit before deduction of amortization XENE|VKTX: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization SUPN (Supernus Pharmaceuticals)|Company profit before taxes, interest and amortization CPRX|Operating profit EBITDA DNLI (Denali Therapeutics Inc.)|Income before deduction of interest, taxes and amortization HRMY|Biohaven Pharmaceutical - Operating profit EBITDA|Profit before interest, taxes and amortization Amylyx Corp|Trevi Therapeutics (TRVI) - Profit before payment of interest, taxes and amortization|praxismedicines.com - Income before deduction of interest, taxes and amortization|AVXL (Anavex Life Sciences Corp.) - Operating profit EBITDA|Operating profit EBITDA CeriBell Inc|Profit before payment of interest, taxes and amortization Prothena Corp (PRTA)|ALEC: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA ANNX (Annexon, Inc.)|Omeros Corp (OMER) - Profit before interest, taxes and amortization|NGNE: Operating profit before deduction of amortization|ACIU - Operating profit EBITDA|VYGR (Voyager Pharma) - Operating profit before deduction of amortization|NMRA: Company profit before taxes, interest and amortization|SCLX (Scilex Holding Company) - Operating profit EBITDA|tevogen.com (TVGN) - Operating income before deduction of amortization|Operating profit EBITDA ACOG|Operating profit before deduction of amortization Cognition Therapeutics Inc. CGTX|Profit before payment of interest, taxes and amortization Inhibikase IKT|Operating income before deduction of amortization Cassava Pharma (SAVA)|ASRT: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization COYA (Coya Therapeutics, Inc.)|VTGN: Operating profit EBITDA|OVID - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Acumen Pharma|Operating profit before amortization CRVO (CervoMed Corporation)|Operating profit EBITDA ATHE|Operating profit before deduction of amortization clene.com CLNN|PepGen - Operating profit before deduction of amortization|Operating income before deduction of amortization Jupiter Neurosciences, Inc. (JUNS)|Relmada - Operating profit EBITDA|Operating profit before depreciation charges Annovis Bio Corporation (ANVS)|Firefly Neuroscience, Inc (AIFF) - Profit before payment of interest, taxes and amortization|Klotho Neurosciences - Income before deduction of interest, taxes and amortization|NRSN (NeuroSense Therapeutics Ltd) - Operating profit EBITDA|Operating profit before deduction of amortization Reviva Pharmaceuticals Holdings Inc. (RVPH)|Operating profit EBITDA MTVA|NRXS - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Helius Medical Technologies HSDT|PASG: Operating profit before amortization|Neuphoria - Operating profit EBITDA|Profit before interest, taxes and amortization Minerva Neurosciences Inc|ATHA (Athira) - Operating profit before deduction of amortization|Addex (ADXN) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Alzamend Neuro Inc.|CYCN: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Protagenic Therapeutics (PTIX)|KTTA - Profit before interest, taxes and amortization|Operating profit EBITDA CRGT (Cortigent)|Operating profit before depreciation charges Avenue Therapeutics Inc|BCLI - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization CARA (caratherapeutics.com)|CHRO: Operating profit EBITDA|Eliem Therapeutics Inc. (ELYM) - Operating profit EBITDA|ITCI (Intra-Cellular Therapies Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization Longboard (LBPH)|Operating profit EBITDA MRNS|NKGN - Profit before interest, taxes and amortization|NeuroBo Pharmaceuticals, Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization SAGE|SNPX: Operating profit before deduction of amortization|Trevena Inc - Company profit before taxes, interest and amortization|VIGL: Operating profit EBITDA|anewmeds.com - Income before deduction of interest, taxes and amortization|CERE (Cerevel Therapeutics, Inc.) - Operating profit EBITDA
